M&A Deal Summary |
|
|---|---|
| Date | 2009-03-16 |
| Target | Innovatis AG |
| Sector | Life Science |
| Buyer(s) | Roche |
| Sellers(s) | VM Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 15M EUR |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 62.4B CHF (2024) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 44 |
| Sector: Life Science M&A | 8 of 31 |
| Type: Add-on Acquisition M&A Deals | 9 of 36 |
| Country: Germany M&A | 1 of 4 |
| Year: 2009 M&A | 2 of 2 |
| Size (of disclosed) | 29 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-03-12 |
Genentech
San Francisco, California, United States Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The Company is based in San Francisco. |
Buy | $46.8B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-03-15 |
PVT Probenverteiltechnik
Waiblingen, Germany PVT Probenverteiltechnik GmbH providing customised automation and workflow solutions for in-vitro diagnostic (IVD) testing in large commercial and hospital laboratories. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 400M EUR |
| Size | Middle-Market |
| Type | Sector Agnostic |
VM Capital (formerly known as Ventizz Capital Partners) is a private equity firm that targets investments in growth-oriented technology businesses operating throughout Europe. VM Capital will consider investing in individual companies as well as acquisitions of secondary private equity transactions. Specific sectors of interest include renewable energy/clean technology, semiconductors, electronics, photonics, materials applicaton, industrial automation, medical technology, IT, and communications. Vorndran looks for control stakes when making investments. The Firm's investment horizon is 3 to 6 years. VM Capital was formed in 2000 and is based in Dusseldorf.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 19 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 6 |
| Country: Germany M&A | 6 of 13 |
| Year: 2009 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-01-22 |
Visioncard
Kematen, Austria Visioncard Kunststoffkarten-Produktions GmbH, based in Kematen/Austria, specializes in producing and printing chipcards and plastic cards. Visioncard is geared to larger volumes and has market-leading competence in all of the standard printing methods (offset, screen, thermal sublimation and thermal transfer printing). |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-10-01 |
Medi-Globe
Stuttgart, Germany Medi-Globe is a developer, producer, and distributor of medical instruments, catheters, implants, and wound care, focusing on minimal-invasive and non-invasive endoscopy applications. Medi-Globe was founded in 1985 and is based in Stuttgart, Germany. |
Sell | - |
